Congress funds uterine fibroid screening for underserved women
H.R. 4392 — Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025 · Filed by Shontel Brown (D-OH) · 54 cosponsors · Introduced Jul 15, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Secretary of Health and Human Services to fund research on early detection of uterine fibroids and award grants to states for screening programs, patient navigation, and public awareness campaigns. It prioritizes funding for geographic areas with socially vulnerable populations at elevated risk, and requires biennial reports to Congress on findings and research developments.
Why we flagged it
The bill's core mechanism is straightforward: federal funding for state-level screening programs and research into uterine fibroid detection and treatment disparities. It is a public-health measure with explicit equity focus, not a regulatory change or industry carve-out.
What the text implies
- By prioritizing socially vulnerable populations, the bill implicitly acknowledges and attempts to address documented racial disparities in uterine fibroid diagnosis and treatment — a health equity signal that may drive broader gynecological-care equity conversations.
- Funding for 'patient navigation services' may expand non-clinical support roles in healthcare, potentially creating new workforce categories and training pathways in underserved regions.
- The mandate to research 'disparities in pain control and management' signals federal acknowledgment that current pain-management protocols may be inequitable, which could influence clinical practice guidelines beyond fibroids.
Who it affects
The bill expands access to screening, early intervention, and patient support services for a condition that disproportionately affects Black women and other vulnerable populations. It mandates research into disparities in pain management and treatment outcomes, directly addressing a documented equity gap in gynecological care.
Who stands to gain
- state health departments
- academic medical centers and research institutions
- gynecological imaging equipment manufacturers
- healthcare systems in underserved areas
Named in the bill
Secretary of Health and Human Services (HHS), States (grant recipients), House Committee on Energy and Commerce, uterine fibroids, Asherman's Syndrome, intrauterine adhesions
Where it stands
54 cosponsors: 54 Democrats.
- Jul 15, 2025 — Introduced · Congress.gov: “Introduced in House”
- Jul 15, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
3 lobbying clients named this bill on 5 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $400,000 in lobbying spend. A filing names 20 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 61% of bills with at least one filing.
Shontel Brown, the sponsor, reported $771,344 in PAC receipts in the 2026 cycle.
- The Metrohealth System — $360,000 on 2 filings
- The Metrohealth System — $40,000 on 1 filing
- Nebraska Hospital Association — $0 on 2 filings
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the full bill text on Jun 8, 2026; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Congress funds uterine fibroid screening for underserved women” QuorumCivic. https://share.quorumcivic.app/bill/119/hr4392 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.